Investigation of the Relationship Between Prostate Cancer and MSMB and NCOA4 Genetic Variants and Protein Expression

Human Mutation

Volumn 34, Issue 1, 2013, Pages 149-156

  Fitzgerald, Liesel M ^a   Zhang, Xiaotun ^b   Kolb, Suzanne ^a   Kwon, Erika M ^c,d   Liew, Ying Ching ^e   Hurtado Coll, Antonio ^e   Knudsen, Beatrice S ^f   Ostrander, Elaine A ^c   Stanford, Janet L ^a,g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

MSMB; NCOA4; Prostate cancer; PSP94

Indexed keywords

ANDROGEN RECEPTOR; BETA MICROSEMINOPROTEIN; MESSENGER RNA; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COACTIVATOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BETA MICROSEMINOPROTEIN GENE; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR RECEPTOR COACTIVATOR 4 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY;

ADULT; AGED; GENE FREQUENCY; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR RECEPTOR COACTIVATORS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TISSUE ARRAY ANALYSIS;

EID: 84871619054     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22176     Document Type: Article

References (25)

1. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. 2008. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168:250-260.
2. Alen P, Claessens F, Schoenmakers E, Swinnen JV, Verhoeven G, Rombauts W, Peeters B. 1999. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Mol Endocrinol 13:117-128.
3. Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, et al. 2005. A psp94-derived peptide pck3145 inhibits mmp-9 secretion and triggers cd44 cell surface shedding: implication in tumor metastasis. Clin Exp Metastasis 22:429-439.
4. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, Chan FL. 1999. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 41:99-109.
5. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, et al. 2009. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 18:1368-75.
6. Cox DR. 1972. Regression models and life tables J R Stat Soc B 34:187-220.
7. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, et al. 2008. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316-321.
8. FitzGerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL. 2009. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 15:3231-3237.
9. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG. 1999. Prostate secretory protein (psp94) suppresses the growth of androgen-independent prostate cancer cell line (pc3) and xenografts by inducing apoptosis. Prostate 38:118-125.
10. Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L, Chin JL, Yamasaki Y, Izawa JI. 2005. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 65:719-723.
11. Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L, Kim E, Ni J, et al. 2004. Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem 279:33438-33446.
12. Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M. 2000. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 164:1819-1824.
13. Kote-Jarai Z, Al Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, et al. 2011. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43:785-791.
14. Li P, Yu X, Ge K, Melamed J, Roeder RG, Wang Z. 2002. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161:1467-1474.
15. Ligr M, Li Y, Zou X, Daniels G, Melamed J, Peng Y, Wang W, Wang J, Ostrer H, Pagano M, Wang Z, Garabedian MJ, et al. 2010. Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol 176:1891-1900.
16. Lilja H, Abrahamsson PA. 1988. Three predominant proteins secreted by the human prostate gland. Prostate 12:29-38.
17. Lou H, Yeager M, Li H, Bosquet JG, Hayes RB, Orr N, Yu K, Hutchinson A, Jacobs KB, Kraft P, Wacholder S, Chatterjee N, et al. 2009. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci USA 106:7933-7938.
18. Mestayer C, Blanchere M, Jaubert F, Dufour B, Mowszowicz I. 2003. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines. Prostate 56:192-200.
19. Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA, Narod SA. 2006. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 175:1291-1297.
20. Niu Y, Yeh S, Miyamoto H, Li G, Altuwaijri S, Yuan J, Han R, Ma T, Kuo HC, Chang C. 2008. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res 68:7110-7119.
21. Peng Y, Li CX, Chen F, Wang Z, Ligr M, Melamed J, Wei J, Gerald W, Pagano M, Garabedian MJ, Lee P. 2008. Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am J Pathol 172:225-235.
22. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, et al. 2010. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 6:e1001204.
23. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK. 1999. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8:881-886.
24. Tekur S, Lau KM, Long J, Burnstein K, Ho SM. 2001. Expression of RFG/ELE1alpha/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: regulation by methylation and sex steroids. Mol Carcinog 30:1-13.
25. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, et al. 2008. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315.